alzheimer disease assessment scale cognitive subscale adas cog 11 item l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item PowerPoint Presentation
Download Presentation
Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item

Loading in 2 Seconds...

play fullscreen
1 / 8

Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item - PowerPoint PPT Presentation


  • 3630 Views
  • Uploaded on

Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item. Increasing scores indicate worsening cognitive function. Rosen WG, et al. Am J Psychiatry . 1984;141:1356-1364. Treatment Difference at Wk 24 on ADAS-cog by Country Core Study—ITT+RDO Population. Austria (N = 9).

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item' - Jimmy


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
alzheimer disease assessment scale cognitive subscale adas cog 11 item
Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item

Increasing scores indicate worsening cognitive function.Rosen WG, et al. Am J Psychiatry. 1984;141:1356-1364.

treatment difference at wk 24 on adas cog by country core study itt rdo population
Treatment Difference at Wk 24 on ADAS-cog by CountryCore Study—ITT+RDO Population

Austria (N = 9)

Belgium (N = 21)

Canada (N = 41)

Germany (N = 63)

Spain (N = 59)

France (N = 63)

Great Britain (N = 48)

Italy (N = 118)

Netherlands (N = 18)

–39.67

46.92

Norway (N = 7)

–29.92

Portugal (N = 9)

Turkey (N = 45)

–20

–10

0

10

20

Favor placebo

Favor Exelon

LS mean difference (95% CI).

duration of nausea and vomiting and number of events per patient core study
Duration of Nausea and Vomiting and Number of Events per PatientCore Study

† Events with no end dates recorded, which may or may not have resolvedby last study visit.

duration of tremor and number of these events per patient core study
Duration of Tremor and Number of These Events per PatientCore Study

1 episode: 34 patients; 2 episodes: 3 patients.

† Events with no end dates recorded, which may or may not have resolved by last study visit.

ae of tremor over time core and extension studies
AE of Tremor Over TimeCore and Extension Studies

Patients are counted more than once if event continues through multiple periods.

change on adas cog sub items at wk 24 core study oc population
Change on ADAS-cog Sub-items at Wk 24Core Study—OC Population

*p < 0.05

† p value based on van Elteren test blocking for country.

dopaminergic agents dose increase after start of study drug core study
Dopaminergic Agents—Dose Increase After Start of Study DrugCore Study

Doses were required to remain unchanged unless clinically indicated.